Field evaluation of a blood based test for active tuberculosis in endemic settings

Aasia Khaliq, Resmi Ravindran, Syed Fahadulla Hussainy, Viswanathan V Krishnan, Atiqa Ambreen, Noshin Wasim Yusuf, Shagufta Irum, Abdul Rashid, Muhammad Jamil, Fareed Zaffar, Muhammad Nawaz Chaudhry, Puneet K. Gupta, Muhammad Waheed Akhtar, Imran Khan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Over 9 million new active tuberculosis (TB) cases emerge each year from an enormous pool of 2 billion individuals latently infected with Mycobacterium tuberculosis (M. tb.) worldwide. About 3 million new TB cases per year are unaccounted for, and 1.5 million die. TB, however, is generally curable if diagnosed correctly and in a timely manner. The current diagnostic methods for TB, including state-of-the-art molecular tests, have failed in delivering the capacity needed in endemic countries to curtail this ongoing pandemic. Efficient, cost effective and scalable diagnostic approaches are critically needed. We report a multiplex TB serology panel using microbead suspension array containing a combination of 11 M.tb. antigens that demonstrated overall sensitivity of 91% in serum/plasma samples from TB patients confirmed by culture. Group wise sensitivities for sputum smear positive and negative patients were 95%, and 88%, respectively. Specificity of the test was 96% in untreated COPD patients and 91% in general healthy population. The sensitivity of this test is superior to that of the frontline sputum smear test with a comparable specificity (30-70%, and 93- 99%, respectively). The multiplex serology test can be performed with scalability from 1 to 360 patients per day, and is amenable to automation for higher (1000s per day) throughput, thus enabling a scalable clinical work flow model for TB endemic countries. Taken together, the above results suggest that well defined antibody profiles in blood, analyzed by an appropriate technology platform, offer a valuable approach to TB diagnostics in endemic countries.

Original languageEnglish (US)
Article numbere0173359
JournalPLoS One
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Hematologic Tests
tuberculosis
Scalability
Suspensions
Tuberculosis
Blood
Automation
Throughput
Plasmas
Antigens
Antibodies
blood
Costs
testing
Serology
Sputum
Workflow
Mycobacterium tuberculosis
automation
Pandemics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Field evaluation of a blood based test for active tuberculosis in endemic settings. / Khaliq, Aasia; Ravindran, Resmi; Hussainy, Syed Fahadulla; Krishnan, Viswanathan V; Ambreen, Atiqa; Yusuf, Noshin Wasim; Irum, Shagufta; Rashid, Abdul; Jamil, Muhammad; Zaffar, Fareed; Chaudhry, Muhammad Nawaz; Gupta, Puneet K.; Akhtar, Muhammad Waheed; Khan, Imran.

In: PLoS One, Vol. 12, No. 4, e0173359, 01.04.2017.

Research output: Contribution to journalArticle

Khaliq, A, Ravindran, R, Hussainy, SF, Krishnan, VV, Ambreen, A, Yusuf, NW, Irum, S, Rashid, A, Jamil, M, Zaffar, F, Chaudhry, MN, Gupta, PK, Akhtar, MW & Khan, I 2017, 'Field evaluation of a blood based test for active tuberculosis in endemic settings', PLoS One, vol. 12, no. 4, e0173359. https://doi.org/10.1371/journal.pone.0173359
Khaliq, Aasia ; Ravindran, Resmi ; Hussainy, Syed Fahadulla ; Krishnan, Viswanathan V ; Ambreen, Atiqa ; Yusuf, Noshin Wasim ; Irum, Shagufta ; Rashid, Abdul ; Jamil, Muhammad ; Zaffar, Fareed ; Chaudhry, Muhammad Nawaz ; Gupta, Puneet K. ; Akhtar, Muhammad Waheed ; Khan, Imran. / Field evaluation of a blood based test for active tuberculosis in endemic settings. In: PLoS One. 2017 ; Vol. 12, No. 4.
@article{ec561c7a2d1b42279ea54c4980540df3,
title = "Field evaluation of a blood based test for active tuberculosis in endemic settings",
abstract = "Over 9 million new active tuberculosis (TB) cases emerge each year from an enormous pool of 2 billion individuals latently infected with Mycobacterium tuberculosis (M. tb.) worldwide. About 3 million new TB cases per year are unaccounted for, and 1.5 million die. TB, however, is generally curable if diagnosed correctly and in a timely manner. The current diagnostic methods for TB, including state-of-the-art molecular tests, have failed in delivering the capacity needed in endemic countries to curtail this ongoing pandemic. Efficient, cost effective and scalable diagnostic approaches are critically needed. We report a multiplex TB serology panel using microbead suspension array containing a combination of 11 M.tb. antigens that demonstrated overall sensitivity of 91{\%} in serum/plasma samples from TB patients confirmed by culture. Group wise sensitivities for sputum smear positive and negative patients were 95{\%}, and 88{\%}, respectively. Specificity of the test was 96{\%} in untreated COPD patients and 91{\%} in general healthy population. The sensitivity of this test is superior to that of the frontline sputum smear test with a comparable specificity (30-70{\%}, and 93- 99{\%}, respectively). The multiplex serology test can be performed with scalability from 1 to 360 patients per day, and is amenable to automation for higher (1000s per day) throughput, thus enabling a scalable clinical work flow model for TB endemic countries. Taken together, the above results suggest that well defined antibody profiles in blood, analyzed by an appropriate technology platform, offer a valuable approach to TB diagnostics in endemic countries.",
author = "Aasia Khaliq and Resmi Ravindran and Hussainy, {Syed Fahadulla} and Krishnan, {Viswanathan V} and Atiqa Ambreen and Yusuf, {Noshin Wasim} and Shagufta Irum and Abdul Rashid and Muhammad Jamil and Fareed Zaffar and Chaudhry, {Muhammad Nawaz} and Gupta, {Puneet K.} and Akhtar, {Muhammad Waheed} and Imran Khan",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0173359",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Field evaluation of a blood based test for active tuberculosis in endemic settings

AU - Khaliq, Aasia

AU - Ravindran, Resmi

AU - Hussainy, Syed Fahadulla

AU - Krishnan, Viswanathan V

AU - Ambreen, Atiqa

AU - Yusuf, Noshin Wasim

AU - Irum, Shagufta

AU - Rashid, Abdul

AU - Jamil, Muhammad

AU - Zaffar, Fareed

AU - Chaudhry, Muhammad Nawaz

AU - Gupta, Puneet K.

AU - Akhtar, Muhammad Waheed

AU - Khan, Imran

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Over 9 million new active tuberculosis (TB) cases emerge each year from an enormous pool of 2 billion individuals latently infected with Mycobacterium tuberculosis (M. tb.) worldwide. About 3 million new TB cases per year are unaccounted for, and 1.5 million die. TB, however, is generally curable if diagnosed correctly and in a timely manner. The current diagnostic methods for TB, including state-of-the-art molecular tests, have failed in delivering the capacity needed in endemic countries to curtail this ongoing pandemic. Efficient, cost effective and scalable diagnostic approaches are critically needed. We report a multiplex TB serology panel using microbead suspension array containing a combination of 11 M.tb. antigens that demonstrated overall sensitivity of 91% in serum/plasma samples from TB patients confirmed by culture. Group wise sensitivities for sputum smear positive and negative patients were 95%, and 88%, respectively. Specificity of the test was 96% in untreated COPD patients and 91% in general healthy population. The sensitivity of this test is superior to that of the frontline sputum smear test with a comparable specificity (30-70%, and 93- 99%, respectively). The multiplex serology test can be performed with scalability from 1 to 360 patients per day, and is amenable to automation for higher (1000s per day) throughput, thus enabling a scalable clinical work flow model for TB endemic countries. Taken together, the above results suggest that well defined antibody profiles in blood, analyzed by an appropriate technology platform, offer a valuable approach to TB diagnostics in endemic countries.

AB - Over 9 million new active tuberculosis (TB) cases emerge each year from an enormous pool of 2 billion individuals latently infected with Mycobacterium tuberculosis (M. tb.) worldwide. About 3 million new TB cases per year are unaccounted for, and 1.5 million die. TB, however, is generally curable if diagnosed correctly and in a timely manner. The current diagnostic methods for TB, including state-of-the-art molecular tests, have failed in delivering the capacity needed in endemic countries to curtail this ongoing pandemic. Efficient, cost effective and scalable diagnostic approaches are critically needed. We report a multiplex TB serology panel using microbead suspension array containing a combination of 11 M.tb. antigens that demonstrated overall sensitivity of 91% in serum/plasma samples from TB patients confirmed by culture. Group wise sensitivities for sputum smear positive and negative patients were 95%, and 88%, respectively. Specificity of the test was 96% in untreated COPD patients and 91% in general healthy population. The sensitivity of this test is superior to that of the frontline sputum smear test with a comparable specificity (30-70%, and 93- 99%, respectively). The multiplex serology test can be performed with scalability from 1 to 360 patients per day, and is amenable to automation for higher (1000s per day) throughput, thus enabling a scalable clinical work flow model for TB endemic countries. Taken together, the above results suggest that well defined antibody profiles in blood, analyzed by an appropriate technology platform, offer a valuable approach to TB diagnostics in endemic countries.

UR - http://www.scopus.com/inward/record.url?scp=85016951404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016951404&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0173359

DO - 10.1371/journal.pone.0173359

M3 - Article

C2 - 28380055

AN - SCOPUS:85016951404

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0173359

ER -